Navigation Links
New Microplegia Service: World's First Low-Potassium, Non-Depolarizing Cardioplegia Available Exclusively from CAPS(R)
Date:4/22/2010

BETHLEHEM, Pa., April 22 /PRNewswire/ -- Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO)

Adenocaine solutions from CAPS arrive prelabeled with CAPS high-contrast labeling to maximize legibility and usability in the operating room, and with tamper evidence for added safety.

"When it comes to high-quality service, CAPS delivers. That means Adenocaine users will now have reliable, convenient and consistent access to our solutions whenever they need them," said David C. Field, Chief Executive Officer for Hibernation Therapeutics. "State-of-the-art cleanroom technology and more than 15 years of experience in the cardioplegia solution market make CAPS the ideal provider of Adenocaine preparations."

CAPS offers the industry's widest range of service options, including same day and next day delivery, 365 days a year.

"We're excited to offer this unique, proprietary, patented solution and service to the cardioplegia market," said Todd Jones, Director of Marketing for CAPS. "Our quality focus and high level of service will complement the innovative solutions from Hibernation Therapeutics."

CAPS meets or exceeds USP Chapter <797> guidelines to safely deliver high-quality admixtures to hospitals from coast to coast.

About Central Admixture Pharmacy Services (CAPS)

State-licensed and an FDA-registered manufacturer, CAPS makes daily deliveries from an unrivaled 22 locations nationwide. Pioneered in 1991, and making more than 200,000 local deliveries annually, CAPS pharmacies reliably operate 365-days a year to dispense labeled, patient-specific and anticipatory IV prescriptions. CAPS is a B. Braun company.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.

Adenocaine is a trademark of Hibernation Therapeutics Global, Ltd.


'/>"/>
SOURCE B. Braun
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
4. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Tainted Chinese Food Ingredients First Discovered in 2005
9. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... Spain , January 23, 2017 ... clinical-stage biopharmaceutical company focused on treatments for calcification ... been enrolled in the Phase IIb "CaLIPSO Study" ... treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) ... patients, in the last stage of chronic kidney ...
(Date:1/23/2017)... Just two weeks remain until legal experts and senior industry leaders involved ... London to discuss the flow of pharmaceutical products post Brexit ... Trade 2017 . In the run up to the show, ... to read in the event download centre . ... Some of those confirmed include: ...
Breaking Medicine Technology:
(Date:1/24/2017)... Scottsdale, Ariz. (PRWEB) , ... January 23, 2017 ... ... , recently analyzed statistics from 140 Buzzies users who entered metrics into the ... Serin's earlier clinical data. The new data showed that within just 30 seconds ...
(Date:1/24/2017)... ... ... The National Council of Alcoholism and Drug Dependence ( NCADD ), in ... designate the last full week of January as National Drug and Alcohol Facts Week. ... As a community, we can advocate for effective treatment, but also especially effective prevention ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... science companies, has achieved ISO 17100:2015 certification following a comprehensive audit performed ... the globally recognized standard that establishes guidance for critical processes within translation, ...
(Date:1/23/2017)... ... January 23, 2017 , ... The iaedp Foundation, recognized ... treatment providers who treat the full spectrum of eating disorder problems, proudly announces ... Council consists of the leading eating disorder treatments centers located throughout the U.S. ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Sharon Kleyne, America’s ... air to educate listeners about the benefits of making new water infrastructure a number ... said, “it’s appropriate that we expect water infrastructure to become a top priority of ...
Breaking Medicine News(10 mins):